---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-044906"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:40:13.061047+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theriva reports positive VIRAGE Phase 2b data for VCN-01 in pancreatic cancer at AACR 2026

## Summary
- VCN-01 + gemcitabine/nab-paclitaxel improved OS and PFS vs GnP alone in metastatic pancreatic cancer patients.
- Later-emerging, higher magnitude, more durable responses observed; benefit maintained across subgroups including liver metastases.
- Patients receiving a second VCN-01 dose showed greater OS and PFS benefit.
- CEO reported alignment with FDA and EMA on proposed pivotal Phase 3 trial; planning study of more frequent VCN-01 dosing.
- Data presented at AACR 2026 (poster CT162) on April 20, 2026.

## SEC filing metadata
- accession: 0001104659-26-044906
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465926044906/0001104659-26-044906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465926044906/tm2612012d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-044906
- JSON: https://secwatch.observer/filing/0001104659-26-044906.json
- Plain text: https://secwatch.observer/filing/0001104659-26-044906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.